The onset of action of Vinaclat tablets is related to the sensitivity of the individual patient to the drug, individual differences, etc. There is no clear time point. According to the metabolism of the drug, the effective blood concentration is reached 2-3 days after taking the drug, and the therapeutic effect is exerted.
Vinacrine is used in combination with azacitidine for the treatment of newly diagnosed adult patients with acute myeloid leukemia who are not suitable for strong induction chemotherapy due to comorbidities, or who are 75 years of age and older. It is administered in combination with azacitidine on a regimen that usually reaches an effective dose in 2-3 days and is administered until disease progression or an intolerable toxic reaction occurs.
There are no clear contraindications to Venekra, but use should be in accordance with the instructions. Adverse reactions such as nausea, diarrhea, constipation, neutropenia, thrombocytopenia, hemorrhage, peripheral edema, vomiting, fatigue, febrile neutropenia, rash, and anemia may occur after administration of the drug. Caution should be exercised in the use of patients with tumor lysis syndrome and neutropenia.
Vinaikra tablets belong to the antitumor drugs, the use of which should be cautious and should be used under the guidance of a professional physician.